Troxerutin

Cardiovascular and cerebrovascular diseases are the category of chronic diseases with the highest fatality rate worldwide, among which edema and thromboembolic complications caused by abnormal vascular permeability are the key intervention directions in clinical treatment. Troxerutin is a flavonoid derivative vascular protective agent. It reduces the risk of thrombosis by inhibiting platelet aggregation, and at the same time can enhance capillary resistance and reduce vascular permeability. It can effectively alleviate tissue damage caused by ischemic cerebrovascular disease, thrombophlebitis, capillary hemorrhage and other diseases, and is a commonly used drug in the basic treatment regimen for middle-aged and elderly patients with cardiovascular and cerebrovascular diseases.

At present, the clinical application of troxerutin in China is dominated by oral preparations and injections. According to public industry data, the domestic market size of troxerutin preparations was approximately RMB 1.27 billion in 2023, with a three-year compound annual growth rate of 4.2%. The demand side continues to grow steadily driven by the expansion of the elderly population base and the rising prevalence of cardiovascular and cerebrovascular diseases. This variety is a mature generic drug. There are more than 70 domestic preparation enterprises approved for production, and the supply of API is mainly from local manufacturers, with obvious cost control advantages, and there is no obvious monopoly pattern of leading enterprises.

Troxerutin has no clear original research enterprise and exclusive trade name. The drug was first developed and marketed by European pharmaceutical companies, and all core compound patents have expired for more than 20 years. At present, the main dosage forms approved in China include tablets, injections and granules. Common specifications include 60mg and 180mg for tablets, 2ml:60mg and 5ml:150mg for injections, etc. A number of domestic troxerutin preparations have been included in the reference preparation catalog issued by the National Medical Products Administration. Up to now, the Center for Drug Evaluation of the National Medical Products Administration has publicly announced more than 20 valid registration numbers for troxerutin API, and the number of approved domestic preparation approval numbers exceeds 300. The domestic supply system is mature and stable. (Data as of June 2025, please refer to the official website of CDE for the latest information)

In response to the needs of troxerutin quality research and compliant production, CATO can provide a full set of impurity reference standards for this API. Most of the products are in stock, and orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the full-process research needs of pharmaceutical enterprises such as declaration, quality testing, and process optimization.